Brainstorm Cell Therapeutics Inc.
| NASDAQ: BCLI | Healthcare / Biotechnology / USA |
| 0.8157 | -0.1243 | -13.22% | Vol 911.11K | 1Y Perf -77.07% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 0.7800 | ASK | 0.9110 | ||
| Open | 0.9700 | Previous Close | 0.9400 | ||
| Pre-Market | - | After-Market | 0.85 | ||
| - - | 0.03 4.20% |
| Target Price | 7.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 758.16 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -2.87 | Earnings Rating | Strong Buy | |
| Market Cap | 36.72M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.23 | |
| Beta | -0.51 |
Today's Price Range 0.78000.9700 | 52W Range 0.92004.56 | 5 Year PE Ratio Range -10.70-6.40 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -15.40% | ||
| 1 Month | -45.98% | ||
| 3 Months | -63.67% | ||
| 6 Months | -48.54% | ||
| 1 Year | -77.07% | ||
| 3 Years | -94.17% | ||
| 5 Years | -79.24% | ||
| 10 Years | -72.81% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -163.09 | |||
ROE last 12 Months | -226.18 | |||
ROA (5Y Avg) | -42.78 | |||
ROA last 12 Months | -119.72 | |||
ROC (5Y Avg) | -139.57 | |||
ROC last 12 Months | -140.63 | |||
Return on invested Capital Q | -74.71 | |||
Return on invested Capital Y | -22.57 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.20 | ||||
| 41.33 | ||||
| - | ||||
| - | ||||
| -3.90 | ||||
| -0.55 | ||||
| 41.33 | ||||
| 0.04 | ||||
| 54.36M | ||||
| Forward PE | -1.78 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 0.80 | ||||
| 0.68 | ||||
| 3.15 | ||||
| - | ||||
| Leverage Ratio | 2.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.15 | -0.27 | -80.00 |
| Q01 2023 | -0.16 | -0.14 | 12.50 |
| Q04 2022 | -0.18 | -0.14 | 22.22 |
| Q03 2022 | -0.15 | -0.19 | -26.67 |
| Q02 2022 | -0.15 | -0.19 | -26.67 |
| Q01 2022 | -0.13 | -0.15 | -15.38 |
| Q04 2021 | -0.20 | -0.17 | 15.00 |
| Q03 2021 | -0.21 | -0.15 | 28.57 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.14 | 6.67 | Positive |
| 12/2023 QR | -0.15 | 11.76 | Positive |
| 12/2023 FY | -0.70 | -14.75 | Negative |
| 12/2024 FY | -0.54 | 8.47 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.14 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 911.11K |
| Shares Outstanding | 45.02K |
| Shares Float | 40.38M |
| Trades Count | 1.92K |
| Dollar Volume | 777.99K |
| Avg. Volume | 421.01K |
| Avg. Weekly Volume | 599.41K |
| Avg. Monthly Volume | 395.96K |
| Avg. Quarterly Volume | 267.65K |
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock closed at 0.8157 per share at the end of the most recent trading day (a -13.22% change compared to the prior day closing price) with a volume of 911.11K shares and market capitalization of 36.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. Brainstorm Cell Therapeutics Inc. CEO is Chaim Lebovits.
The one-year performance of Brainstorm Cell Therapeutics Inc. stock is -77.07%, while year-to-date (YTD) performance is -50.26%. BCLI stock has a five-year performance of -79.24%. Its 52-week range is between 0.92 and 4.56, which gives BCLI stock a 52-week price range ratio of -2.87%
Brainstorm Cell Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 41.33, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -119.72%, a ROC of -140.63% and a ROE of -226.18%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Brainstorm Cell Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Brainstorm Cell Therapeutics Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Brainstorm Cell Therapeutics Inc. is Strong Buy (1), with a target price of $7, which is +758.16% compared to the current price. The earnings rating for Brainstorm Cell Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Brainstorm Cell Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Brainstorm Cell Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 29.15, ATR14 : 0.14, CCI20 : -128.54, Chaikin Money Flow : -0.54, MACD : -0.20, Money Flow Index : 7.35, ROC : -44.13, RSI : 18.75, STOCH (14,3) : 4.03, STOCH RSI : 0.00, UO : 18.92, Williams %R : -95.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Brainstorm Cell Therapeutics Inc. in the last 12-months were: Lindborg Stacy (Buy at a value of $20 355)
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
CEO: Chaim Lebovits
Telephone: +1 201 488-0460
Address: 1325 Avenue of Americas, New York 10019, NY, US
Number of employees: 40
